Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
University of California, San Diego, California 92093, USA. paisen@ucsd.edu
In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.
Images from this publication.See all images (1)Free text
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on